Investor Presentaiton
2022 Financial Highlights
DELIVERED +9.5% CORE REVENUE GROWTH
Biotechnology +6%, Life Sciences +9.5%, Diagnostics +13.5%, EAS +8%
High-single digit base business core revenue growth
ACCELERATED HIGH-IMPACT GROWTH INVESTMENTS
- Accelerated innovation with more than $1.7B in R&D investments
Capex of over $1B drove capacity expansions in our bioprocessing
and genomics businesses
STRONG ADJUSTED EPS GROWTH & FREE CASH FLOW
31st consecutive year that FCF exceeded Net Income
+9.5%
CORE REVENUE
GROWTH
+60BPS
CORE OMX
(operating profit margin expansion)
>100%
FCF / NI
CONVERSION
+9.0%
ADJUSTED DILUTED
NET EPS GROWTH
*Base Business core revenue growth excludes the impact of revenue from COVID-19 testing.
2022 was a tremendous year for Danaher
3
DANAHERView entire presentation